Workflow
Avalo Therapeutics(AVTX)
icon
Search documents
Avalo Therapeutics(AVTX) - 2018 Q4 - Annual Report
2019-03-18 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______to______ Commission File No. 001‑37590 Cerecor Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...